In just over a decade, genetically engineered mice have brought dramatic changes to the biomedical sciences, offering basic researchers ways to detect the influences of single genes and more clinically oriented investigators compellingly close models of human disease.
| Of Aging |
A small California foundation that does not accept grant applications has nonetheless gained ground as an unusually flexible seed funder and advocate for research in the biology of aging.
Researchers and officials in this field say the Glenn Foundation for Medical Research, endowed and run by venture capitalist Paul Glenn, is helping to crack the door on a broad area of biological investigation that still commands only a portion of the federal budget for medical research.
Glenn "does fill some holes we can't handle," says Huber Warner, deputy associate director of the program on the biology of aging at the National Institute on Aging (NIA). That program had just $44...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?